Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...

An experimental antibody has outperformed an established immunotherapy in a head-to-head trial for one of the harder-to-treat forms of lung cancer. In patients with advanced squamous non-small-cell ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...

Please provide your email address to receive an email when new articles are posted on . A retrospective analysis showed pathological complete response was achieved by more than half of patients.

AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: ...

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD- (L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring ...